$11.23 0.20 (+1.81%)
11/20/2009 4:00 PM

ISIS Pharmaceuticals, Inc. (ISIS)

CAPS Rating: 4 out of 5

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.

Current Price $11.23 Mkt Cap $1.1B
Open $10.95 P/E Ratio 920.50
Prev. Close $11.03 Div. (Yield) N/A (N/A)
Daily Range $10.90 - $11.24 Volume 1,435,173
52-Wk Range $9.90 - $18.81 Avg. Daily Vol. 1,697,000

ISIS News and Commentary

Caps

How do you think ISIS will perform vs the S&P 500?

Add Stock to Watchlist

All Members

478 Outperform
26 Underperform
 

All-Star Members

84 Outperform
7 Underperform
 

Wall Street

13 Outperform
0 Underperform
 

Top ISIS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Teknowizz (90.91)
Submitted August 04, 2009

Nice pipeline (http://www.isispharm.com/Pipeline/index.htm) of antisense (SiRNA) drugs, which they partner or license for commercialisation. Several drugs for multiple indications in P3. Cashflow is OK, likely to become profitable by end of year or… More

synergize (99.10)
Submitted May 15, 2008

Please use the daily charts before you read farther to understand what I mean.

Most of the time when the price of this stock gaps up, it goes down. Its noticeable gap up was on 8-Jan-2008 only to go down for several weeks. The investors of… More

ISIS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about ISIS.

Recs

0
Member Avatar TMFBiologyFool (93.17) Submitted: 11/17/2009 2:20:23 PM : Outperform Start Price: $11.25 ISIS Score: +1.26

Mipomersen works. Side effects might be too great to be used for everyone, but it'll get used in HoFH patients.

Recs

0
Member Avatar LookknforFun (< 20) Submitted: 11/17/2009 8:57:06 AM : Outperform Start Price: $13.40 ISIS Score: -14.85

Mipomersen will be the first Antisense drug to market in about 20 years and only the second antisense drug to market. Isis has approx. 18 drugs in its portfolio and an approval of Mipomersen will sharply increase its share price as investors will notice and value its pipeline better. Better cash position may also result in a possible buyout of the Co. however, due to the structure and complexity of its partnerships it is highly unlikely to be acquired. Isis will remain independent until it finds a true block buster drug with over 2B in revenue which it is Co marketing.

I expect Isis to trade in the 25-30 range in the next 12-18 months.

Recs

0
Member Avatar JerryDreamer (< 20) Submitted: 8/17/2009 1:48:04 AM : Underperform Start Price: $15.37 ISIS Score: +38.17

When the overly optimistic FOMC says that household spending will be "constrained" by sluggish income growth, ongoing job losses, lower household wealth, and tight credit AND Shanghai stocks hit a seven-week low, then you know this bear market rally is finally over!

Leaderboard

Find the members with the highest scoring picks in ISIS.

Score Leader

princemot

princemot (35.94) Score: +119.04

The Score Leader is the member with the highest score across all their picks in ISIS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
Santa22 < 20 9/22/2006 Outperform 3Y $7.02 +59.97% -11.51% +71.48
asterionc2 79.02 9/27/2006 Outperform 5Y $7.10 +58.17% -12.94% +71.11
jdmckeehan < 20 10/2/2006 Outperform 3Y $7.18 +56.41% -13.01% +69.41
leadtip 51.63 8/25/2006 Outperform 1Y $7.09 +58.39% -9.97% +68.36
John8464 < 20 9/15/2006 Outperform 1Y $7.23 +55.33% -12.50% +67.82
gsstock 62.06 8/23/2006 Outperform 5Y $7.14 +57.28% -10.41% +67.69
schmosly 23.79 10/3/2006 Outperform 1Y $7.31 +53.63% -12.96% +66.58 1 Comment
stanhutchings < 20 8/28/2006 Outperform 5Y $7.20 +55.97% -10.03% +66.01 1 Comment
mcgoatcheese 93.16 9/8/2006 Outperform 5Y $7.58 +48.15% -10.52% +58.67
Unklesam101 31.08 5/31/2006 Outperform 3Y $7.60 +47.72% -7.99% +55.71 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCantorFitz 20.50 7/29/2009 Outperform NS $17.87 -37.16% +12.85% -50.01
TrackJimCramer 36.31 3/16/2009 Outperform 3W $13.57 -17.24% +46.81% -64.05
TrackMorganJos < 20 1/9/2009 Outperform NS $14.41 -22.07% +22.17% -44.24
TrackJimCramer 36.31 1/6/2009 Underperform 3W $14.86 -8.68% -18.84% -10.16 3/16/2009 @ $13.57
TrackCollinsStew 68.85 12/16/2008 Outperform NS $11.25 -0.18% +27.14% -27.32
TrackZacks 70.74 11/11/2008 Outperform 3M $15.12 -10.32% +22.70% -33.02 11/11/2009 @ $13.56 1 Comment
TrackJimCramer 36.31 8/27/2008 Outperform 3W $17.73 -16.19% -27.33% +11.15 1/7/2009 @ $14.86
TrackWachovia < 20 10/11/2007 Outperform NS $16.02 -29.90% -26.94% -2.96
TrackWIG 90.70 10/1/2007 Outperform 3Y $14.95 +16.19% +1.01% +15.18 10/16/2007 @ $17.37
TrackEveillard 88.00 9/30/2007 Outperform NS $14.97 +5.21% -4.17% +9.39 12/31/2007 @ $15.75 1 Comment
TrackJefferies 31.78 7/19/2007 Outperform NS $11.33 -0.88% -25.78% +24.89
TrackNeedham < 20 7/9/2007 Outperform NS $10.60 +5.94% -24.79% +30.73
TrackTobinSmith < 20 6/22/2007 Outperform 1Y $9.53 +17.84% -23.51% +41.34
TrackZacks 70.74 6/7/2007 Outperform 3M $9.16 +55.13% -33.73% +88.86 10/20/2008 @ $14.21 1 Comment
TrackFortisBank 85.69 3/20/2007 Outperform NS $8.93 +25.76% -17.57% +43.33
TrackLehmanBros 66.51 1/29/2007 Outperform NS $11.06 +1.54% -18.31% +19.85
TrackAGEdwards 84.75 11/10/2006 Outperform NS $10.37 +8.29% -15.92% +24.21
TrackCowenandCo 69.87 11/9/2006 Outperform NS $10.19 +10.21% -16.46% +26.66
TrackJimCramer 36.31 3/24/2006 Underperform 3W $8.91 +98.99% -1.14% -100.13 8/27/2008 @ $17.73
TrackJimCramer 36.31 3/1/2006 Outperform 3W $8.14 +9.46% +0.91% +8.55 3/24/2006 @ $8.91

Featured Broker Partners